Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease

Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease

Background: Several studies have shown that high plasma lipoprotein(a) concentrations are associated with an increased risk of arteriosclerotic cardiovascular disease. Thus, Lp(a) has emerged as a new therapeutic target. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ar...

Full description

Bibliographic Details
Main Authors:	Seung Woo Choi, Joan Kim, Gyeong Won Jang, Young Shin Lee, Jin Sun Park, Jung Myung Lee, Hyung Oh Kim, Hyemoon Chung, Jong Shin Woo, Woo Shik Kim, Weon Kim
Format:	Article
Language:	English
Published:	MDPI AG 2022-03-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	coronary artery disease evolocumab high-sensitivity C-reactive protein lipoprotein(a) low-density lipoprotein cholesterol
Online Access:	https://www.mdpi.com/2308-3425/9/4/101

Similar Items

Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies
by: Martha L. Daviglus, et al.
Published: (2021-01-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins
by: Chaoxuan Wang, et al.
Published: (2024-03-01)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
by: Peter P. Toth, et al.
Published: (2017-10-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial
by: Tomoaki Okada, et al.
Published: (2022-05-01)

Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
by: Andreja Rehberger Likozar, et al.
Published: (2022-12-01)

Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab
by: Federica Fogacci, et al.
Published: (2023-12-01)

Application of evolocumab in patients with coronary heart disease complicated with mild renal insufficiency
by: Zhang Yu, Wu Bin, Feng Jiaxu, Wang Rutao, Yuan Ming
Published: (2023-10-01)

Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study
by: Meng-Meng Yu, et al.
Published: (2023-05-01)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
by: Borislav Borissov, et al.
Published: (2017-01-01)

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
by: Heidi T. May, et al.
Published: (2019-03-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019-10-01)

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol
by: Jing Gao, et al.
Published: (2021-11-01)

Effect of Empagliflozin with or without the Addition of Evolocumab on HDL Subspecies in Individuals with Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EXCEED-BHS3 Trial
by: Isabella Bonilha, et al.
Published: (2024-04-01)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
by: Peter Willeit, et al.
Published: (2020-12-01)

Age‐Related Associations of Low‐Density Lipoprotein Cholesterol and Atherosclerotic Cardiovascular Disease: A Nationwide Population‐Based Cohort Study
by: Han Na Jung, et al.
Published: (2022-05-01)

Relationship between Lipoprotein(a) and Dyslipidemia in the Elderly over 60 Years
by: Yo-Han Seo, et al.
Published: (2022-06-01)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
by: Henry CA, et al.
Published: (2016-04-01)

Association of High-Density Lipoprotein Cholesterol Phenotypes with the Risk of Cardiovascular Diseases and Mortality: A Cohort Study in Korea
by: Ga Eun Nam, et al.
Published: (2022-04-01)

Associations between remnant lipoprotein cholesterol and central systolic blood pressure in a Chinese community-based population: a cross-sectional study
by: Kaiyin Li, et al.
Published: (2021-06-01)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

Characterization and quantification of serum lipoprotein subfractions by capillary isotachophoresis: relationships with lipid, apolipoprotein, and lipoprotein levels
by: Alexandra Schlenck, et al.
Published: (1999-11-01)

LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
by: U. Julius, et al.
Published: (2018-09-01)

Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field
by: Michal Olejarz, et al.
Published: (2024-04-01)

Evaluation of plasma lipids and lipoproteins in patients with psoriasis
by: B Yaghmaei, et al.
Published: (1994-12-01)

Higher Serum Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio Is Associated with Increased Mortality among Incident Peritoneal Dialysis Patients
by: Hee-Won Noh, et al.
Published: (2021-12-01)

High-density lipoprotein cholesterol to low-density lipoprotein cholesterol ratio in early assessment of disease severity and outcome in patients with acute pancreatitis admitted to the ICU
by: Qin Wu, et al.
Published: (2020-05-01)

Coronary risk prediction by the correlation of total cholesterol/high-density lipoprotein, triglyceride/high-density lipoprotein, low-density lipoprotein/high-density lipoprotein ratios, non-high-density lipoprotein, apolipoprotein-B, and high-sensitivity C-reactive protein with low-density lipoprotein in Indian patients under statin therapy
by: A K Badrinath, et al.
Published: (2019-01-01)

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study
by: Milan Gupta, et al.
Published: (2023-10-01)

Comparison of low-density lipoprotein cholesterol level calculated using the modified Martin/Hopkins estimation or the Friedewald formula with direct homogeneous assay measured low-density lipoprotein cholesterol
by: Istvan Reiber, et al.
Published: (2020-08-01)

Association Between Serum High‐Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW‐CKD
by: Ki Heon Nam, et al.
Published: (2019-03-01)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
by: Kosmas CE, et al.
Published: (2018-10-01)

Comparison of soymilk and probiotic soymilk effects on serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in diabetic Wistar rats
by: Mina Babashahi, et al.
Published: (2015-04-01)

High density lipoproteins and oxidative stress in breast cancer
by: Gabriele Mazzuferi, et al.
Published: (2021-10-01)

Mathematical Modelling of Material Transfer to High-Density Lipoprotein (HDL) upon Triglyceride Lipolysis by Lipoprotein Lipase: Relevance to Cardioprotective Role of HDL
by: Svetlana Schekatolina, et al.
Published: (2022-07-01)

Cholesterol efflux capacity is associated with lipoprotein size and vascular health in mild to moderate psoriasis
by: Alexander R. Berg, et al.
Published: (2023-02-01)

Role of Lipoproteins in the Pathophysiology of Breast Cancer
by: Santhi Latha Pandrangi, et al.
Published: (2022-05-01)

A comparison of anion-exchange and steric-exclusion HPLC assays of mouse plasma lipoproteins
by: Jonathan Neyer, et al.
Published: (2005-08-01)